- The Israeli Ministry of Health has accepted for review BioCryst Pharmaceuticals Inc's BCRX application for Orladeyo to prevent recurrent attacks in patients with hereditary angioedema (HAE) 12 years and older.
- The Israeli Ministry of Health also has granted an accelerated review.
- In addition, BioCryst has entered into a distribution and supply agreement granting Neopharm Ltd to commercialize Orladeyo in Israel.
- Price Action: BCRX shares are up 1.6% at $15.86 during the premarket session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
